HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, James Chih‐Hsin Yang et al.|Journal of Clinical Oncology|2023Cited by 224
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapyEmilia Montagna, Marco Colleoni, Vincenzo Bagnardi et al.|Annals of Oncology|2014Cited by 54